DDInter813 DDInter927
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Gemifloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Gemifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Gemifloxacin {u} (Compound) causes {v} (Side Effect) Tendon rupture
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Triamcinolone
Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Gemifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Gemifloxacin (Compound) causes Tendon rupture (Side Effect)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Gemifloxacin may lead to a major life threatening interaction when taken with Nilotinib
Gemifloxacin may lead to a major life threatening interaction when taken with Triamcinolone